title: C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
authors.affiliation: Corresponding author: Odd Erik Johansen, odd-erik.johansen@boehringer-ingelheim.com.
authors.forename: Odd Erik
authors.initials: OE
authors.lastname: Johansen
authors.forename: Bernhard O
authors.initials: BO
authors.lastname: Boehm
authors.forename: Valdemar
authors.initials: V
authors.lastname: Grill
authors.forename: Peter A
authors.initials: PA
authors.lastname: Torjesen
authors.forename: Sudipta
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: Sanjay
authors.initials: S
authors.lastname: Patel
authors.forename: Kristiane
authors.initials: K
authors.lastname: Wetzel
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Woerle
mesh_terms: D000328:Adult; D000368:Aged; D015551:Autoimmunity; D002096:C-Peptide / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069476:Linagliptin; D008297:Male; D008875:Middle Aged; D011687:Purines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D002096:C-Peptide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069476:Linagliptin; D011687:Purines; D011799:Quinazolines; D013453:Sulfonylurea Compounds; C057619:glimepiride